Type of HRT and risk of venous thromboembolism

BMJ

Volumn 336, Issue 7655, 2008, Pages 1203-1204

  Roberts, Helen ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ETHINYLESTRADIOL; SEX HORMONE BINDING GLOBULIN;

BODY MASS; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DRUG SAFETY; EDITORIAL; GENE MUTATION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; FEMALE; INTRADERMAL DRUG ADMINISTRATION; NOTE; ORAL DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 44849101479     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39556.666944.80     Document Type: Editorial

References (14)

1. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; doi: 10.1136/bmj.39555.441944.BE.
2. Curb JD, Prentice RL, Bray PF, Langer RD, van Horn L, Barnabei VM, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-80.
3. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SAA, Brzyski R, et al; for the WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45.
4. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the Esther study. Circulation 2007;115:840-5.
5. Smith N, Heckbert S, Lemaitre R, Reiner AP, Lumley T, Rosendaal FR, et al. Conjugated equine estrogens, esterified estrogens, prothrombotic variants and the risk of venous thrombosis in postmenopausal women. Arterioscler Thromb Vasc Biol 2006;26:2807-12.
6. Van den Heuval MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinyl estradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168-74.
7. White T, Ozel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 2006;74:293-6.
8. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109:339-46.
9. Clinical Trials. Boston collaborative drug surveillance programme. Postmarketing study of ortho evra and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of EE in relation to non-fatal venous thromboembolism, ischaemic stroke and myocardial infarction. 2006. www.clinicaltrials.gov/ct2/show/NCT00511784.
10. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7.
11. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofield PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study group. BJOG 2002;109:1056-62.
12. Beral V; for the Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419-27.
13. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes. JAMA 2004;291:1610-20.
14. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:168-82.